Mayne Pharma Group Ltd 2023 Annual Report
Company: Mayne Pharma Group Ltd
Sector: Manufacturing
Country: Australia
Year: 2023
Type: Annual Report
Pages: 90
The report describes FY23 as a transitional year in which the company completed the sale of Metrics Contract Services and its US Retail Generics business while licensing three US women's-health products and prenatal vitamins. Continuing-operations revenue was reported as 183,586 $'000, although the company recorded a substantial net loss after tax. Its sustainability disclosures focus on healthy and safe workplaces, EHS management, reducing Scope 1 and 2 emissions, energy efficiency, renewable sources, water use, responsible products and affordable medicines.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.